Everything below concerns cyclic heptapeptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Melanotan II; MT-II; N-acetyl-norleucyl-cyclo[Asp-His-D-Phe-Arg-Trp-Lys] amide | Naming follows peptide convention; the numeral distinguishes it from melanotan-1 |
| Molecular formula | C50H69N15O9 | Includes the lactam bridge; no counter-ion assumed |
| Monoisotopic mass | 1023.53 Da | Free base; salts and counter-ions shift the observed value |
| Appearance | White to off-white lyophilised powder | Batch-to-batch colour variation is not itself proof of impurity |
| Typical analytical method | RP-HPLC purity determination with ESI-MS identity confirmation | Retention time alone does not establish sequence identity |
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
=== Non-substrate-like inhibitors === Non-substrate-like inhibitors do not take after dipeptidic nature of DPP-4 substrates. They are non-covalent inhibitors and usually have an aromatic ring that occupies the S1-pocket, instead of the proline mimetic. In 1999, Merck started a drug development program on DPP-4 inhibitors. When they started internal screening and medicinal chemistry program, two DPP-4 inhibitors were already in clinical trials, isoleucyl thiazolidide (P32/38) and NVP-DPP728 from Novartis. Merck in-licensed L-threo-isoleucyl thiazolidide and its allo stereoisomer. In animal studies, they found that both isomers had similar affinity for DPP-4, similar in vivo efficacy, similar pharmacokinetic and metabolic profiles. Nevertheless, the allo isomer was 10-fold more toxic. The researchers found out that this difference in toxicity was due to the allo isomer's greater inhibition of DPP-8 and DPP-9 but not because of selective DPP-4 inhibition. More research also supported that DPP-4 inhibition would not cause compromised immune function. Once this link between affinity for DPP-8/DPP-9 and toxicity was discovered, Merck decided on identifying an inhibitor with more than a thousandfold affinity for DPP-4 over the other dipeptidases. For this purpose, they used positional scanning libraries.
== See also == Advanced Landing Ground – a type of semi-permanent bases in Kent, France, Belgium, Netherlands and occupied Germany Air Ministry Experimental Station Chain Home – radar defence system developed during the Second World War Class A airfield – airfields constructed to Air Ministry specifications during the Second World War List of Battle of Britain airfields List of North African airfields during World War II List of Royal Air Force stations, current MoD and RAF stations List of Royal Air Force Satellite Landing Grounds List of V Bomber dispersal bases
Kasie Hines is the current NCIS forensics specialist and a graduate student at the medical school in New York where Ducky is guest teaching in season 15. Ducky hires her as his assistant to help keep him on schedule on a book he is writing about past cases. However, when a past cold case resurfaces in "One Man's Trash", Ducky returns to NCIS to assist in the investigation, bringing a reluctant Kasie along with him to help and meet his co-workers. While Kasie is friendly towards most of Gibbs' team to the point of giving hugs, she is noticeably cold towards Abby Sciuto, making no attempts to connect with her despite staying in her guest room. This frustrates Abby, who believes that Kasie doesn't like her despite her attempts to be friendly, especially since, as Abby later learns from Ducky, Kasie has a degree in forensic science. After witnessing Kasie encourage Ducky to use the case to inspire his creativity for the book, Abby confronts Kasie, who admits that she is a fan of Abby's work and freaked out internally when she met her, and the two develop a close friendship. Following Abby's resignation from NCIS, Gibbs hires Kasie in "Fallout" to fill in for her temporarily until he finds a permanent replacement, which she agrees to do with Abby's blessing. However, this slightly unsettles the rest of the members of Gibbs' team, who are still trying to cope with Abby's departure and Reeves’ death. Kasie becomes the permanent replacement forensics specialist in Season 16.
== Research == Lemborexant is under development for the treatment of circadian rhythm sleep disorders, sleep apnea, and chronic obstructive pulmonary disease. As of February 2022, it is in phase 2 clinical trials for circadian rhythm sleep disorders and phase 1 trials for sleep apnea and chronic obstructive pulmonary disease.
== Research == Rosiglitazone was thought to be able to benefit patients with Alzheimer's disease who do not express the ApoE4 allele, but the phase III trial designed to test this showed that rosiglitazone was ineffective in all patients, including ApoE4-negative patients. Rosiglitazone may also treat mild to moderate ulcerative colitis, due to its anti-inflammatory properties as a PPAR ligand. Rosiglitazone has been investigated as an agent that may expedite body fat redistribution into a more feminine shape in trans women who have had little fat redistribution from hormone replacement therapy, due to thiozolidinediones' effects on body fat metabolism.
Sources: en.wikipedia.org
He was arrested and pleaded not guilty to all charges. His trial opened in April 2023. The Specialist Prosecutor's Office sought a sentence of 45 years imprisonment for war crimes and persecution of Serb and Roma minorities. In September 2026, he was convicted and sentenced to 25 years in prison for war crimes including the murder of 96 people and the torture of 303 people. The Trial Panel found Thaçi not guilty of crimes against humanity. There have been controversies regarding Thaçi's role in the KLA and allegations about him being involved in organized crime.
== Awards == Broadbent was elected as a Fellow of the Royal Society Te Apārangi in 2021. The Society said "One of her most notable contributions is the development and testing of healthcare robots, especially for improving outcomes in rest-home and dementia care and chronic illness...this is innovative interdisciplinary work of exceptional quality".
After Zwangendaba's death the Ngoni split into several groups amid civil war over succession, and his son M'mbelwa led the largest contingent to settle in modern-day Mzimba District in Malawi c. 1850. The Ngoni incorporated numerous local groups into the state, and often raided villages on the fringes of the state for captives, cattle, and food, causing widespread disruption in the region over the following decades. The state was later incorporated into the British Central Africa Protectorate.
=== Prokaryotes expression vector === Promoter - commonly used inducible promoters are promoters derived from lac operon and the T7 promoter. Other strong promoters used include Trp promoter and Tac-Promoter, which are a hybrid of both the Trp and Lac Operon promoters. Ribosome binding site (RBS) - follows the promoter, and promotes efficient translation of the protein of interest. Translation initiation site - Shine-Dalgarno sequence enclosed in the RBS, 8 base-pairs upstream of the AUG start codon.
Sources: en.wikipedia.org
=== Waxing and oiling === Historically, light waxing and oiling were the first treatments used in ancient times, providing a wetting effect, thereby enhancing the colour and lustre. This treatment is more or less acceptable by tradition, especially because treated turquoise is usually of a higher grade to begin with. Oiled and waxed stones are prone to "sweating" under even gentle heat or if exposed to too much sun, and they may develop a white surface film or bloom over time. (With some skill, oil and wax treatments can be restored.)
==== Alkaline phosphatase ==== Alkaline phosphatase from E. coli can be purified using a DEAE-Cellulose matrix. A. phosphatase has a slight negative charge, allowing it to weakly bind to the positively charged amine groups in the matrix. The enzyme can then be eluted out by adding buffer with higher salt concentrations.
=== High-throughput === Due to the highly time-consuming and work-intensive standard procedure, the method of in-gel digestion was limited to a relatively small number of protein spots to be processed at a time. Therefore, it has been found to be the ideal object for automation ambitions to overcome these limitations for industrial and service laboratories. Today, in laboratories where in-gel digestion is performed in high-throughput quantities, the procedure is usually automated. The degree of automation varies from simple pipetting robots to highly sophisticated all-in-one solutions, offering an automated workflow from gel to mass spectrometry. The systems usually consist of a spot picker, a digestion robot, and a spotter. The advantages of the automation other than the larger number of spots to be processed at a time are the reduced manual work and the improved standardisation. Due to the many handling steps of the method, the results of the manual process could vary depending on the dexterity of the user and the risk of contamination is high. Therefore, the quality of the results is described to be one main advantage of the automated process. Drawbacks of automated solutions are the costs for robots, maintenance and consumables as well as the complicated setup of the process. Since the automated picking needs digitised information of the spot location, the analysis of the gel image for relevant spots has to be done by software requiring standardised imaging methods and special scanners.
Electroanalytical methods measure the electric potential in volts and/or the electric current in amps in an electrochemical cell containing the analyte. These methods can be categorized according to which aspects of the cell are controlled and which are measured. The three main categories are potentiometry (the difference in electrode potentials is measured), coulometry (the cell's current is measured over time), and voltammetry (the cell's current is measured while actively altering the cell's potential).
Yusuf Shihab and Bashir Shihab II were the only Maronite rulers of the Emirate of Mount Lebanon. The Shihab family allied with Muhammad Ali of Egypt during his occupation of Syria, but was deposed in 1840 when the Egyptians were driven out by an Ottoman-European alliance, leading soon after to the dissolution of the Shihab emirate. Despite losing territorial control, the family remains influential in modern Lebanon, with some members having reached high political office. The Khazens opposed the creation of the "Double Qaimaqmate" in Mount Lebanon in the 1840s, which divided Mount Lebanon into Druze and Christian-run sectors, and were incensed at the appointment of a sheikh from the mixed Druze-Christian Abu'l-Lama family as the qaimaqam (deputy governor) of the Maronite section of the Qaimaqamate. The Khazens feared that such an appointment would formally subordinate them to the Abu'l-Lama sheikhs. Several Khazen family members became destitute in the 1830s and 1840s and Khazen influence over the Maronite Church waned. To compensate for their economic, social and political stagnation, the Khazens increased their pressure on the peasants of Kisrawan in the late 1850s, while also spending extravagantly. The "Druze-Christian alliance" during this century was the major factor enabling the Shehab dynasty to maintain power.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.
The natural hormone is a linear tridecapeptide that is rapidly degraded in circulation. Melanotan-2 is shortened, cyclised, N-terminally acetylated, and carries a D-amino acid substitution, all of which slow enzymatic breakdown.
No national medicines regulator has approved melanotan-2 for therapeutic or cosmetic use. In several jurisdictions it is treated as an unapproved prescription medicine, and its legal classification differs from country to country.
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.